市場調查報告書
商品編碼
1370643
注射避孕藥市場- 按類型(僅黃體酮注射劑{長效醋酸甲羥孕酮})、年齡層(15-24 歲、25-34 歲)、作用持續時間(短效注射避孕藥)、最終用戶、全球預測、 2023-2032Injectable Contraceptives Market - By Type (Progesterone-only Injectables {Depot Medroxyprogesterone Acetate}), Age Group (15-24 Years, 25-34 Years), Duration of Action (Short-acting Injectable Contraceptives), End-user, Global Forecast, 2023-2032 |
2023 年至 2032 年間,全球注射避孕藥市場的年複合成長率將達到 3.5%。由於注射避孕藥領域的創新和研究發現不斷增加,該產業將持續擴張。例如,2023年10月,印度醫學研究委員會(ICMR)在避孕領域取得了突破性進展,成功完成了世界首創的男性注射避孕藥的臨床試驗。這些試驗證明了該方法的安全性和顯著的有效性,沒有任何明顯的副作用。第三階段試驗涉及 303 名年齡在 25 歲至 40 歲之間的候選人。 ICMR的臨床試驗結果最近發表在國際公認的男科學雜誌上。
配方、給藥方法和功效的不斷進步正在擴大女性和男性的避孕選擇。這些創新不僅擴大了選擇,還提高了避孕注射劑的便利性和可靠性,從而推動了避孕注射劑市場的成長。
整個注射避孕藥市場根據類型、最終用戶和地區進行分類。
複方注射避孕藥細分市場將在 2023 年至 2032 年間經歷重大發展。這些配方包含多種激素,可為女性提供高效的節育選擇。 CIC 的便利性和有效性以及副作用的減少使其越來越受歡迎。隨著女性尋求可靠的避孕選擇,注射避孕藥市場前景對複方注射避孕藥的需求持續成長。
婦科診所領域從 2023 年到 2032 年將實現顯著的年複合成長率。這些醫療機構擴大提供注射避孕藥,作為女性方便有效的節育選擇。婦科診所提供的專業知識和服務使其成為尋求專家指導和護理的人的自然選擇。這一趨勢反映出人們更廣泛地轉向可及且可靠的避孕解決方案,從而促進了注射避孕藥市場的擴張。
歐洲注射避孕藥市場從 2023 年到 2032 年將呈現可觀的年複合成長率。這歸因於該地區不斷進步的醫療基礎設施以及女性對避孕選擇的認知不斷提高。歐洲女性正在轉向注射避孕藥作為安全、方便的選擇。由於注重生殖健康和知情選擇,歐洲對注射避孕藥具的需求將會成長,使其成為全球市場的重要部分。
Global Injectable Contraceptives Market will witness 3.5% CAGR between 2023 and 2032. The industry is set on expansion due to the growing number of innovations and research discoveries in the realm of injectable contraceptives. For instance, in October 2023, a groundbreaking development in the contraceptive field came from the Indian Council of Medical Research (ICMR), which successfully concluded clinical trials for the world's pioneering injectable male contraceptive. These trials demonstrated both safety and remarkable effectiveness of the method, devoid of any significant adverse effects. The phase-3 trials involved 303 candidates aged between 25 and 40 years. The results of ICMR's clinical trials were recently published in the internationally accessible Andrology journal.
Ongoing advancements in formulation, delivery methods, and efficacy are expanding contraceptive options for women and men. These innovations are not only broadening choice but also improving the convenience and reliability of injectable contraceptives, thus fueling the injectable contraceptive market growth.
The overall Injectable Contraceptives Market is classified based on type, end-user, and region.
Combined injectable contraceptives segment will undergo significant development from 2023 to 2032. These formulations include a combination of hormones that offer highly effective birth control options for women. The convenience and efficacy of CICs, in line with reduced side effects, have contributed to their increasing popularity. As women seek reliable contraceptive choices, the demand for combined injectable contraceptives continues to grow in the injectable contraceptives market outlook.
Gynaecology clinics segment will register a notable CAGR from 2023 to 2032. These healthcare facilities are increasingly offering injectable contraceptives as a convenient and effective birth control option for women. The specialized knowledge and services provided in gynaecology clinics make them a natural choice for those seeking expert guidance and care. This trend reflects the broader shift toward accessible and reliable contraceptive solutions, contributing to the injectable contraceptives market expansion.
Europe injectable contraceptives market will showcase an appreciable CAGR from 2023 to 2032. This is attributed to the region's progressive healthcare infrastructure and the increasing awareness among women regarding contraceptive options. European women are turning to injectable contraceptives as a safe and convenient choice. With a focus on reproductive health and informed choices, Europe's demand for injectable contraceptives will grow, making it a prominent segment within the global market.
DATA TABLES